Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTHENON: Phase I/IIa Study of AZD4956 Alone and with Saruparib in HRR-defective Solid Tumours
2025-524171-22-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of AZD4956 in solid neoplasms and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Planned start Sep 2026; status: authorised.
02
Drugs
AZD4956
03
Conditions
solid neoplasmsmetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-524171-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524171-22-00.